Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sabrina Elmshäuser"'
Autor:
Evangelos Pavlakis, Michelle Neumann, Nastasja Merle, Ronja Wieboldt, Michael Wanzel, Viviane Ponath, Elke Pogge von Strandmann, Sabrina Elmshäuser, Thorsten Stiewe
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-21 (2023)
Abstract Background TP53, encoding the tumor suppressor p53, is frequently mutated in various cancers, producing mutant p53 proteins (mutp53) which can exhibit neomorphic, gain-of-function properties. The latter transform p53 into an oncoprotein that
Externí odkaz:
https://doaj.org/article/4196caed645b473fadaf09c6ecb0eca3
Autor:
Natella I. Enukashvily, Nikita V. Ponomartsev, Avanee Ketkar, Roman Suezov, Anna V. Chubar, Andrey D. Prjibelski, Daria D. Shafranskaya, Sabrina Elmshäuser, Corinna U. Keber, Vera N. Stefanova, Andrey L. Akopov, Ursula Klingmüller, Petra I. Pfefferle, Thorsten Stiewe, Matthias Lauth, Anna I. Brichkina
Publikováno v:
Cell Death and Disease, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract The abnormal tumor microenvironment (TME) often dictates the therapeutic response of cancer to chemo- and immuno-therapy. Aberrant expression of pericentromeric satellite repeats has been reported for epithelial cancers, including lung cance
Externí odkaz:
https://doaj.org/article/37e5b9bbd3824838a0df904eaa43bbc0
Autor:
Nastasja Merle, Sabrina Elmshäuser, Florian Strassheimer, Michael Wanzel, Alexander M. König, Julianne Funk, Michelle Neumann, Katharina Kochhan, Frederik Helmprobst, Axel Pagenstecher, Andrea Nist, Marco Mernberger, André Schneider, Thomas Braun, Tilman Borggrefe, Rajkumar Savai, Oleg Timofeev, Thorsten Stiewe
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-22 (2022)
Abstract Background In vivo gene editing of somatic cells with CRISPR nucleases has facilitated the generation of autochthonous mouse tumors, which are initiated by genetic alterations relevant to the human disease and progress along a natural timeli
Externí odkaz:
https://doaj.org/article/d980d18d5f1b484f966f534df0c944fb
Autor:
Boris Klimovich, Laura Meyer, Nastasja Merle, Michelle Neumann, Alexander M. König, Nikolaos Ananikidis, Corinna U. Keber, Sabrina Elmshäuser, Oleg Timofeev, Thorsten Stiewe
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-18 (2022)
Abstract Background Impaired p53 function is one of the central molecular features of a tumor cell and even a partial reduction in p53 activity can increase the cancer risk in mice and men. From a therapeutic perspective it is noteworthy that tumor c
Externí odkaz:
https://doaj.org/article/a5fc0464584d420f93f35003a2b8b8ba
Autor:
Niklas Gremke, Pierfrancesco Polo, Aaron Dort, Jean Schneikert, Sabrina Elmshäuser, Corinna Brehm, Ursula Klingmüller, Anna Schmitt, Hans Christian Reinhardt, Oleg Timofeev, Michael Wanzel, Thorsten Stiewe
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
mTORC1 is a key mediator of drug resistance and also regulates autophagy. In this study, the authors demonstrate that cancer cells with acquired drug resistance exibit metabolic vulnerabilities mediated by high levels of mTORC1 and the consequent inh
Externí odkaz:
https://doaj.org/article/9653fbfc87624dd8b531af0c6eab20e9
Autor:
Julianne Funk, Maria Klimovich, Evangelos Pavlakis, Michelle Neumann, Daniel Drangenstein, Maxim Noeparast, Pascal Hunold, Anna Borowek, Dimitrios-Ilias Balourdas, Katharina Kochhan, Nastasja Merle, Imke Bullwinkel, Michael Wanzel, Sabrina Elmshäuser, Andrea Nist, Tara Procida, Marek Bartkuhn, Katharina Humpert, Marco Mernberger, Rajkumar Savai, Andreas C. Joerger, Thorsten Stiewe
The tumor suppressor geneTP53is the most frequently mutated gene in various cancers. Unlike other tumor suppressors,TP53is mostly hit by missense mutations, of which more than 2,000 have been described in cancer patients. To take advantage ofTP53muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bd897fd30da296ebc5a45f07280c622
https://doi.org/10.1101/2023.03.10.531074
https://doi.org/10.1101/2023.03.10.531074
Autor:
Boris Klimovich, Nastasja Merle, Michelle Neumann, Sabrina Elmshäuser, Andrea Nist, Marco Mernberger, Daniel Kazdal, Albrecht Stenzinger, Oleg Timofeev, Thorsten Stiewe
Publikováno v:
Oncogene. 41:1011-1023
The tumor suppressive transcription factor p53 is frequently inactivated in cancer cells by missense mutations that cluster in the DNA binding domain. 30% hit mutational hotspot residues, resulting in a complete loss of transcriptional activity and m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d5994cf9230988a9c7fad86dfff5273
https://doi.org/10.1038/s41388-021-02141-5
https://doi.org/10.1038/s41388-021-02141-5
Autor:
Boris Klimovich, Laura Meyer, Nastasja Merle, Michelle Neumann, Alexander M. König, Nikolaos Ananikidis, Corinna U. Keber, Sabrina Elmshäuser, Oleg Timofeev, Thorsten Stiewe
Publikováno v:
Journal of experimentalclinical cancer research : CR. 41(1)
Background Impaired p53 function is one of the central molecular features of a tumor cell and even a partial reduction in p53 activity can increase the cancer risk in mice and men. From a therapeutic perspective it is noteworthy that tumor cells ofte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32f9a3bcfa5268a8dc59b77fea0b599c
https://pubmed.ncbi.nlm.nih.gov/35232479
https://pubmed.ncbi.nlm.nih.gov/35232479
Autor:
Marco Mernberger, Boris Klimovich, Jean Schneikert, Thorsten Stiewe, Samet Mutlu, Andrea Nist, Maria Klimovich, Sabrina Elmshäuser, Oleg Timofeev
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Mouse studies demonstrating regression of p53-null tumors following reinstatement of functional p53 have fueled the development of p53 reactivating drugs. However, successful p53 reactivation responses have only been formally demonstrate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d648db61cf1469df2ffc9a9c6927a781
https://doi.org/10.1073/pnas.1910255116
https://doi.org/10.1073/pnas.1910255116
Autor:
Alexander Brobeil, Marco Mernberger, Boris Klimovich, Boris Lamp, Ulrich Wenig, Kernt Köhler, Julia Noll, Samet Mutlu, Sabrina Elmshäuser, Thorsten Stiewe, Michael Wanzel, Oleg Timofeev, Stefan Gattenlöhner, Andrea Nist, Jean Schneikert, Evangelos Pavlakis
Publikováno v:
The EMBO Journal
Engineered p53 mutant mice are valuable tools for delineating p53 functions in tumor suppression and cancer therapy. Here, we have introduced the R178E mutation into the Trp53 gene of mice to specifically ablate the cooperative nature of p53 DNA bind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f76ab45a910ffa3fad0ef91399c685c0
http://europepmc.org/articles/PMC6792016
http://europepmc.org/articles/PMC6792016